5d 1m 3m 1y 5y 10y
There are no Focus articles on ARUXF.
There are no Transcripts on ARUXF.
There are no News articles on ARUXF.
ARUXF vs. ETF Alternatives
Wednesday, Nov 242010, 8:26 AMThe FDA approves Axiron, Eli Lilly's (LLY) topical solution for testosterone replacement therapy in men. The U.S. testosterone market, estimated at $1B, is set to grow 20% annually. Acrux (ARUXF.PK), Lilly's Australian partner on the drug, rose 9.1% in Aussie trading. |Wednesday, Nov 242010, 8:26 AM| Comment!
Instablogs are blogs which are instantly set up and networked within the Seeking Alpha community. Instablog posts are not selected, edited or screened by Seeking Alpha editors, in contrast to contributors' articles.